Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

BTK Inhibitor Calms Pemphigus Vulgaris With Low-Dose Steroids

Key clinical point: PRN1008 improved disease activity and induced remission in pemphigus.

Major finding: At the end of the 24-week study, 70% experienced a clinical response and 25% experienced remission.

Study details: The open-label study comprised 27 patients.

Disclosures: Principia Biopharma is developing the molecule and sponsored the study. Dr. Murrell designed the study and reported a financial relationship with Principia, as well as with numerous other pharmaceutical companies.


Murrell D et al. AAD 2019, Session S034.